All the Drug Class Drugs
Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml. VIAL FOR INJECT: 1 x 12.5 mg/50 ml
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
Antiplatelet Agent. Ticagrelor 60 mg, 90 mg. F.C. TABS: 56. Pts. taking Ticagrelor should also take ASA dly., unless specific. contraind.
Follow. an init. dose of ASA, Ticagrelor should be used with a mainten. dose of ASA of 75-150 mg.
Acute coron. syndr.: Ticagrelor tmt. should be initi. with a single 180 mg load. dose (2 tabs. of 90 mg) and then contin. at 90 mg ×2/d.
Tmt. with Ticagrelor 90 mg ×2/d is recomm. for up to 12 mnths. in ACS pts. unless discont. is clinic. indic.
Ticagrelor 60 mg ×2/d dly. is the recomm. dose when an extend. tmt. is requir. for pts. with a hist. of MI of at least 1 year and a high risk of an atherothrombot. event. Tmt. may be started without interrupt. as contin. ther. after the init. 1 -year tmt. with Ticagrelor 90 mg or other adenosine diphosphate (ADP) recept. inhib. ther. in ACS pts. with a high risk of an atherothrombot. event. Tmt. can also be init. up to 2 yrs. from the MI, or within 1 year after stop. prev. ADP recept. inhibit. tmt.
In pts. with ACS, premat. discont. with any antiplat. ther., includ. Ticagrelor, could result in an incr. risk of cardiovasc. death, or MI due to the pt’s. underlying dis. Therefore, premature discont. of tmt. should be avoided. See lit.
Indic. co-admin. with ASA, is for the preven. of atherothrombot. events in adult pts. with - acute coron. syndr. (ACS) or - a hist. of MI and a high risk of develop. an atherothrombot.
Limitations of use: 90 mg ×2/d during the 1st year after an ACS event follow. by 60 mg ×2/d for addit. 2 yrs.
C/I: Hypersens. Active pathology. bleed. History of intracran. haemorr. Severe hep. impair. Co-admin. with strong CYP3A4 inhib. (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).
Antiplatelet Agent. Acetylsalicylic Acid 100 mg. E.C. TABS: 28/30. 75/100 mg dly aft.
diagn. MI: Initial: 150 mg dly. Short
term up to 300 mg dly as reqd. See lit.
Prim. prevent. coron. heart dis. in pts. at
incr. risk, second. prevent. thrombot.
C/I: Known hypersens. to drug/drugs of
same group., bleed. disords., active/
history of recurr. peptic ulcer/
haemorrhage, child/adolesc. under 20
yrs suffering/recover. from influenza/
chicken pox (for fear of Reye’s syndr.),
cerebral hemorrh., sev. heart fail.,
history of bleed./perfor. of the stomach/
intestine related to salic. acid/other
Antiplatelet Agent. Clopidogrel (as hydrogen sulphate) 75 mg. TABS: 30. 75 mg dly as single dose
with/out food. Non-ST seg. elevat.
acute coronary syndr. (unstable
angina/non-Q-wave MI). Initial: 300
mg load. dose, cont. with 75 mg 1 x dly
(with ASA 75-325 mg dly - optimal:
100 mg dly). Max benefit within 3
mths. but can cont. for up to 12 mths.
ST seg. elevat. acute MI: 75 mg 1 x dly.
Load dose (in comb. with ASA with/
without thrombolyts.): Pts. over 75 yrs:
Comb. ther. as soon as possible aft.
onset sympts. Cont. for at least 4 wks.
Under 18 yrs: Safety/efficacy not
Prevent. atherothromb: In pts. with M.I.
(from a few days until less than 35 days),
ischem. stroke (from 7 days-6 mths) or
estab. periph. art. dis. History recent M.I.,
recent stroke, estab. periph. art. dis, to
reduce rate of comb. endpoint new
ischem. stroke (fatal or not), new M.I. (fatal
or not), and other vasc. death. Acute
coron. syndr. [non-ST seg. elevat. acute
coron. syndr. (unstable angina/non-Qwave
M.I.) or ST seg. elevat. acute M.I. ] in
comb. with ASA in medically treat. pts.
eligible for thrombolyt. ther., percutan.
coron. intervent. (with/out stent) or CABG,
to decr. rate comb. endpoint CV death,
M.I., stroke or refract. ischem.